SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 11h ago SEC0001011438-26-000695
Passive stake amendment
Actionable Insight • Neutral

Monitor whether Affinity Asset Advisors converts this passive 13G to an active 13D, which would signal a shift in intent. The warrant-based position and beneficial ownership limitation suggest a structured investment rather than open-market accumulation.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Affinity Asset Advisors and Michael Cho filed an amended Schedule 13G disclosing a new passive stake of 1,573,517 shares (6.5%) of Karyopharm Therapeutics as of September 30, 2026, all held via warrants subject to a 9.99% beneficial ownership limitation. This is a new filer for this issuer; the stake is passive and the impact is neutral given the small market cap and warrant-based position.

Key Financial Metrics

Stake
6.5%
Stake Value
$65.0K
Investor
Affinity Asset Advisors, LLC
Investor Type
hedge fund

Key Facts

  • Affinity Asset Advisors and Michael Cho report beneficial ownership of 1,573,517 shares (6.5%) as of September 30, 2026
  • All shares are issuable upon exercise of warrants, subject to a 9.99% beneficial ownership limitation
  • This is a new filing by Affinity Asset Advisors; no prior 13G/A on file for this issuer
  • The percentage is based on 24,254,977 shares outstanding (including the warrant shares)
  • The filing is passive under Rule 13d-1(b); the filer certifies no intent to change or influence control

Financial Impact

Stake of 1,573,517 shares valued at approximately $65,000 based on market cap of $1M and 24.3M shares outstanding

ownership percentage

Risk Factors

  • Warrant exercise could increase dilution if the beneficial ownership limitation is waived or adjusted
  • The company's tiny $1M market cap makes any large holder's actions potentially impactful on liquidity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001011438-26-000695
Document: 0001011438-26-000695-index.html0001011438-26-000695
Document: 0001011438-26-000695.txt0001011438-26-000695

Track record

30 reports on KPTI

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
  2. Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
  4. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
  5. Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
  6. Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
  7. Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
  8. Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
  9. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
  10. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
Showing 10 of 30

US Market Status

Market Closed · Opens in 5h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026